Enoxaparin use while Breastfeeding
Drugs containing Enoxaparin: Lovenox, Clexane, Lovenox HP, Clexane Forte
Enoxaparin Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited information indicates that maternal enoxaparin in doses up to 40 mg daily do not to cause any adverse effects in breastfed infants. Because its large molecular weight of 2000 to 8000 daltons, enoxaparin would not be expected to be excreted into breasmilk or to be absorbed from breastmilk by the infant. No special precautions are required.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Ten women received enoxaparin 20 mg and 2 received 40 mg daily by subcutaneous injection from the prepartum to the postpartum period. At 5 to 7 days postpartum, anti-Xa activity (a measurement of enoxaparin anticoagulant activity) was undetectable in their 12 completely breastfed term neonates 1.5 to 3 hours after they were breastfed for at least 5 days. No bleeding was detected among the infants during maternal enoxaparin therapy.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
1. Guillonneau M, de Crepy A, Aufrant C et al. [Breast-feeding is possible in case of maternal treatment with enoxaparin]. Arch Pediatr (Paris). 1996;3:513-4. PMID: 8763733
CAS Registry Number
- Low Molecular Weight Heparin
LactMed Record Number
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.